Search the Newsreel

Barclays Maintains Forte Biosciences(FBRX.US) With Hold Rating, Maintains Target Price $77

Barclays has reiterated its 'Hold' rating on Forte Biosciences (FBRX.US) and maintained its target price at $77. This indicates that the financial institution sees the stock performing in line with the broader market and expects its value to remain stable at the specified price …

Forte Biosciences (NASDAQ:FBRX) Releases Earnings Results, Misses Estimates By $0.09 EPS

Forte Biosciences (NASDAQ:FBRX) announced its quarterly earnings, reporting a loss of $0.97 EPS, which missed analysts' consensus estimate of a $0.88 loss by $0.09. The company's shares are trading near their 52-week high, with significant trading volume, and institutional investors holding a large percentage …

Forte Biosciences (FBRX) to be acquired by argenx in $77-per-share cash deal

Hedge Funds Favor argenx (ARGX) Over Forte Biosciences, Inc. (FBRX): Argenx Agrees to Buy Forte Biosciences

argenx SE (NASDAQ:ARGX) agreed to buy Forte Biosciences, Inc. (NASDAQ:FBRX) for about $2.2 billion in cash, paying $77 a share, a roughly 40% premium to Forte's Friday closing price. The deal adds Forte's experimental drug FB102, which analysts describe as a first-in-class anti-CD122 antibody, …

Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX

Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Forte Biosciences, Inc. (FBRX) to argenx SE for $77.00 per share in cash. KSF is evaluating whether this price adequately values Forte Biosciences and if the process leading to the sale was …

FBRX Stock Alert: Halper Sadeh LLC is Investigating Whether Forte Biosciences, Inc. is Obtaining a Fair Price for its Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the proposed sale of Forte Biosciences, Inc. (NASDAQ: FBRX) to argenx for $77.00 per share in cash. The investigation aims to determine if Forte's board failed to secure the best possible price for shareholders, …

Alger Associates (FBRX) trims Forte Biosciences ownership to a 4.6% stake

Alger Associates, Inc. has filed an amended Schedule 13G, disclosing a reduced beneficial ownership of 4.6% in Forte Biosciences, Inc. (FBRX), totaling 935,514 shares. The firm holds sole voting power over 930,512 shares and sole dispositive power over all 935,514 shares, indicating no shared …

Janus Henderson Group Ltd. (NASDAQ: FBRX) discloses 2.5% beneficial stake in Forte

Janus Henderson Group Ltd. has reported a beneficial ownership of 2.5% of Forte Biosciences, Inc. (FBRX) common stock, totaling 521,016 shares, including those obtainable through warrant exercises. These shares are held across various client accounts managed by Janus Henderson's investment adviser subsidiaries, referred to …

Argenx Announces Commencement Of Tender Offer To Acquire Forte Biosciences, Inc. >ARGX.BT

Argenx has announced the commencement of a tender offer to acquire Forte Biosciences, Inc. This strategic move aims to expand Argenx's portfolio and market position. The acquisition is expected to close following regulatory approvals and the successful tender of Forte Biosciences' shares.

argenx launches tender offer for Forte Biosciences at $77 per share

argenx has launched a tender offer to acquire Forte Biosciences for $77.00 per share in cash. The offer, which is not subject to a financing condition, is set to expire on August 26, 2026, and has been recommended by Forte's Board of Directors. argenx …

argenx to acquire Forte Biosciences (NASDAQ: FBRX) in $77 cash tender

argenx BV, through its subsidiary Avena Merger Sub Inc., has initiated a cash tender offer to acquire all outstanding shares of Forte Biosciences, Inc. (NASDAQ: FBRX) for $77.00 per share. This offer is detailed in an Offer to Purchase dated August 6, 2026, and …

Forte Biosciences (FBRX) to Release Earnings on Thursday

Enterprise value to revenue forward of Forte Biosciences, Inc. – NASDAQ:FBRX

Price to sales forward of Forte Biosciences, Inc. – NASDAQ:FBRX

This article provides financial information for Forte Biosciences, Inc. (NASDAQ: FBRX), focusing on its "Price to sales forward" metric. It appears to be a stub or a section of a larger financial data report from TradingView, offering a quick overview of the company's financial …

Argenx to acquire Forte in $2.2B deal for ‘differentiated’ immune drug

Argenx is set to acquire Forte Biosciences in a deal valued up to $2.2 billion, aiming to bolster its immunology pipeline with Forte's experimental drug, FB102. This drug, targeting the CD122 protein, has shown early promise in treating autoimmune conditions like celiac disease and …

Forte Biosciences stock hits 52-week high at 76.69 USD

Forte Biosciences Inc (FBRX) stock reached a 52-week high of $76.69, reflecting a 667.18% surge over the past year and significant investor interest, despite warnings from InvestingPro about potential overvaluation due to its high beta. This surge follows Argenx's announcement to acquire Forte Biosciences …

Healthcare Briefs: Forte Biosciences Acquired In $2.2 Billion Deal By Amsterdam-based Agenx

Forte Biosciences has been acquired by Amsterdam-based Agenx for $2.2 billion, adding Forte's investigational therapy FB102 for autoimmune diseases to Agenx's pipeline. Additionally, Fort Worth-based TimelyCare received URAC accreditation for its AI use in healthcare, Lantern Pharma got EMA clearance for a Phase 1b/2 …

The Charts Reveal Significant Price Movement in Forte Biosciences Stock Ahead of Argenx’s Acquisition Announcement

The article highlights suspicious price movements in Forte Biosciences (FBRX) and Argenx (ARGX) stock prior to the public announcement of Argenx's acquisition of Forte Biosciences. FBRX saw a significant price jump beginning June 29, weeks before the July 27 acquisition announcement, suggesting potential insider …

Argenx To Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, To Its Immunology Pipeline

Argenx will acquire Forte Biosciences, Inc. to add FB102, a first-in-class anti-CD122 antibody, to its immunology pipeline. The acquisition involves Argenx paying Forte Biosciences stockholders approximately $4.60 per share in cash, with an additional contingent value right of up to $25.00 per share tied …

Forte Biosciences (Nasdaq:FBRX) - Stock Analysis

This article provides a stock analysis of Forte Biosciences (FBRX), a clinical-stage biopharmaceutical company. It highlights recent news including argenx's agreement to acquire Forte Biosciences for $2.2 billion and positive Phase 1b trial results for FB102 in vitiligo and celiac disease. The report also …

Forte Biosciences (NASDAQ:FBRX) Stock Rating Lowered by Evercore

Forte Biosciences (FBRX) Agrees To argenx Takeover As Tender Offer Nears

argenx SE has announced a definitive agreement to acquire Forte Biosciences (FBRX) through a cash tender offer, a transaction approved by both company boards and expected to close soon. This acquisition places Forte Biosciences in deal territory, with its stock closing recently at $76.65, …

argenx Deal Would Add FB102 Antibody With Vitiligo, Celiac Data

argenx announced a definitive agreement to acquire Forte Biosciences for $77 per share in cash, totaling approximately $2.2 billion. This acquisition will add Forte's lead asset, FB102, a first-in-class anti-CD122 antibody with promising Phase 1b data in vitiligo and celiac disease, to argenx's immunology …

Forte Biosciences Acquired by Dutch Pharma Firm for $2.2B

Dallas-based biopharmaceutical company Forte Biosciences has been acquired by Dutch firm Argenx for $2.2 billion. The acquisition centers around Forte's experimental drug FB102, which has shown positive results in early-stage clinical trials for treating autoimmune diseases like vitiligo and celiac disease. Argenx aims to …

argenx signs agreement to buy Forte Biosciences for $2.2bn

argenx has entered into a definitive agreement to acquire Forte Biosciences for approximately $2.2 billion in total equity value. The acquisition, expected to close in Q3 2026, will add Forte Biosciences' first-in-class anti-CD122 antibody, FB102, to argenx’s immunology portfolio. The deal represents an 86% …

Forte Biosciences (FBRX) was downgraded to a Hold Rating at Evercore ISI

Forte Biosciences (FBRX) Stock Looks Stretched On Book Value Yet Strong On Pipeline Hope

Argenx’s $2B Forte Bio Acquisition Brings Autoimmune Playbook to Prevalent Disorders

Argenx is acquiring Forte Biosciences in a $2.2 billion deal to expand into more prevalent autoimmune conditions. Forte's lead drug, FB102, a CD122-targeting antibody, has shown promising early clinical results in celiac disease and vitiligo. This acquisition complements Argenx's existing portfolio, leveraging their experience …

Argenx deepens immuno expertise with $2.2B Forte Biosciences buy

Argenx is acquiring Forte Biosciences for approximately $2.2 billion to significantly expand its immunology portfolio. The key asset in this acquisition is Forte's investigational antibody therapy, FB102, which has shown promise in early studies for treating vitiligo and celiac disease. Argenx views FB102 as …

Forte Biosciences to be acquired by argenx

argenx is set to acquire Forte Biosciences for $77 per share in cash, totaling approximately $2.2 billion, representing an 86% premium. This strategic acquisition will integrate Forte's FB102, a first-in-class anti-CD122 antibody with promising Phase 1b results in vitiligo and celiac disease, into argenx's …

Why Forte Biosciences Shares Are Trading Higher By 39%; Here Are 20 Stocks Moving Premarket

Forte Biosciences (FBRX) shares surged 38.9% in pre-market trading following the announcement that argenx SE (ARGX) plans to acquire the company for $77 per share in cash, totaling $2.2 billion. Other significant movers included T3 Defense Inc. (DFNS), Ohmyhome Ltd. (OMH), and Matinas BioPharma …

Forte Biosciences Inc (FBRX) Financial Health: Profitability & Balance Sheet Analysis

argenx to Acquire Forte Biosciences for $2.2 Billion, Gains FB102 Antibody

argenx is set to acquire Forte Biosciences for $2.2 billion, gaining full ownership of FB102, an anti-CD122 antibody. This acquisition follows positive Phase 1b data for FB102 in vitiligo and celiac disease, with Phase 2 celiac results expected by the end of 2026. The …